BRIEF published on 10/24/2024 at 19:35, 1 year 4 months ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 4 months ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 4 months ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 4 months ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 6 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 6 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 8 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
PRESS RELEASE published on 07/01/2024 at 09:22, 1 year 8 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 1 year 8 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 1 year 8 months ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
Published on 03/06/2026 at 00:00, 6 hours ago Redwood AI Exploring Opportunities for its Proprietary AI Platform Across Multiple Industries
Published on 03/05/2026 at 22:55, 7 hours 5 minutes ago Pivotree to Release Fourth Quarter 2025 Financial Results
Published on 03/05/2026 at 20:00, 10 hours ago PPX Hosts Medical Outreach Campaign for Local Communities
Published on 03/05/2026 at 17:55, 12 hours 5 minutes ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 16 hours ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/06/2026 at 05:45, 15 minutes ago CGTN: How China sets stage for strong start to its next Five-Year Plan, opens global opportunities
Published on 03/06/2026 at 02:00, 4 hours ago Hisense showcases record-breaking 116-inch UX TV at iconic winter sports venue
Published on 03/06/2026 at 00:20, 5 hours 40 minutes ago LiuGong at CONEXPO 2026 | Electric and Integrated Solutions
Published on 03/05/2026 at 18:40, 11 hours 20 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 11 hours 25 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
